PMID- 33833762
OWN - NLM
STAT- MEDLINE
DCOM- 20210923
LR  - 20210923
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 12
DP  - 2021
TI  - Identification of NY-ESO-1(157-165) Specific Murine T Cell Receptors With 
      Distinct Recognition Pattern for Tumor Immunotherapy.
PG  - 644520
LID - 10.3389/fimmu.2021.644520 [doi]
LID - 644520
AB  - New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a promising target 
      for T-cell receptor-engineered T cell (TCR-T) therapy, and targeting the human 
      leukocyte antigen (HLA)-A2 restricted NY-ESO-1(157-165) epitope has yielded 
      remarkable clinical benefits in the treatment of multiple advanced malignancies. 
      Herein, we report the identification of two NY-ESO-1(157-165) epitope-specific 
      murine TCRs obtained from HLA-A(*)0201 transgenic mice. NY-ESO-1(157-165) 
      specific TCRs were isolated after vaccinating HLA-A2 transgenic mice with epitope 
      peptides. HZ6 and HZ8 TCRs could specifically bind to NY-ESO-1(157-165)/HLA-A2 
      and were capable of cytokine secretion with engineered Jurkat T cells and primary 
      T cells upon recognition with K562 target cells expressing the single-chain 
      trimer (SCT) of NY-ESO-1(157-165)/HLA-A2. The reactivity profiles of the HZ6 and 
      HZ8 TCRs were found to be distinct from one another when co-cultured with K562 
      target cells carrying alanine-substituted NY-ESO-1(157-165) SCTs. The binding 
      characterization revealed that the recognition pattern of the HZ6 TCR to 
      NY-ESO-1(157-165)/HLA-A2 was substantially different from the widely used 1G4 
      TCR. These findings would broaden the understanding of immunogenicity of the 
      NY-ESO-1(157-165), and the two identified TCRs may serve as promising candidates 
      for the future development of TCR-T therapy for tumors.
CI  - Copyright (c) 2021 Zhang, Sun, Wang, Zeng, Cao, Han, Tan and Gao.
FAU - Zhang, Helin
AU  - Zhang H
AD  - Research Network of Immunity and Health (RNIH), Beijing Institutes of Life 
      Science, Chinese Academy of Sciences, Beijing, China.
AD  - University of Chinese Academy of Sciences, Beijing, China.
FAU - Sun, Meng
AU  - Sun M
AD  - Research Network of Immunity and Health (RNIH), Beijing Institutes of Life 
      Science, Chinese Academy of Sciences, Beijing, China.
AD  - University of Chinese Academy of Sciences, Beijing, China.
FAU - Wang, Jie
AU  - Wang J
AD  - Key Laboratory of Pathogenic Microbiology and Immunology, Institute of 
      Microbiology, Chinese Academy of Sciences, Beijing, China.
AD  - College of Life Sciences, Jiangxi Science and Technology Normal University, 
      Nanchang, China.
FAU - Zeng, Bin
AU  - Zeng B
AD  - College of Life Sciences, Jiangxi Science and Technology Normal University, 
      Nanchang, China.
AD  - College of Pharmacy, Shenzhen Technology University, Shenzhen, China.
FAU - Cao, Xiaoqing
AU  - Cao X
AD  - Beijing Chest Hospital, Capital Medical University, Beijing, China.
FAU - Han, Yi
AU  - Han Y
AD  - Beijing Chest Hospital, Capital Medical University, Beijing, China.
FAU - Tan, Shuguang
AU  - Tan S
AD  - University of Chinese Academy of Sciences, Beijing, China.
AD  - Key Laboratory of Pathogenic Microbiology and Immunology, Institute of 
      Microbiology, Chinese Academy of Sciences, Beijing, China.
FAU - Gao, George F
AU  - Gao GF
AD  - Research Network of Immunity and Health (RNIH), Beijing Institutes of Life 
      Science, Chinese Academy of Sciences, Beijing, China.
AD  - University of Chinese Academy of Sciences, Beijing, China.
AD  - Key Laboratory of Pathogenic Microbiology and Immunology, Institute of 
      Microbiology, Chinese Academy of Sciences, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210323
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (HLA-A*02:01 antigen)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (peptide NY-ESO-1 157-165)
SB  - IM
MH  - Animals
MH  - HEK293 Cells
MH  - HLA-A2 Antigen/genetics/*metabolism
MH  - Humans
MH  - *Immunotherapy
MH  - Jurkat Cells
MH  - K562 Cells
MH  - Mice
MH  - Mice, Transgenic
MH  - Neoplasm Proteins/*immunology
MH  - Neoplasms/genetics/immunology/*therapy
MH  - Peptide Fragments/*immunology
MH  - Receptors, Antigen, T-Cell/genetics/*immunology
MH  - T-Lymphocytes/*immunology
PMC - PMC8021954
OTO - NOTNLM
OT  - New York esophageal squamous cell carcinoma 1
OT  - T cell receptor-engineered-T cell
OT  - T-cell receptor
OT  - human leukocyte antigen-A*0201
OT  - tumor
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/04/10 06:00
MHDA- 2021/09/24 06:00
PMCR- 2021/01/01
CRDT- 2021/04/09 06:26
PHST- 2020/12/21 00:00 [received]
PHST- 2021/02/15 00:00 [accepted]
PHST- 2021/04/09 06:26 [entrez]
PHST- 2021/04/10 06:00 [pubmed]
PHST- 2021/09/24 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2021.644520 [doi]
PST - epublish
SO  - Front Immunol. 2021 Mar 23;12:644520. doi: 10.3389/fimmu.2021.644520. eCollection 
      2021.